Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cone-rod homeobox protein (CRX) is a critical transcription factor belonging to the OTX family, primarily expressed in retinal photoreceptor cells and the pineal gland (UniProt: O43186). It plays a fundamental role in the differentiation and survival of rod and cone cells by regulating the expression of essential phototransduction genes such as rhodopsin and color opsins (NCBI Gene: 1406). Mutations in the CRX gene are a significant cause of inherited retinal dystrophies, including Leber congenital amaurosis type 7 and cone-rod dystrophy type 2, which lead to progressive vision loss (OMIM: 602225). While CRX is not currently targeted by conventional small-molecule drugs, it is a major focus for advanced therapeutic modalities like AAV-mediated gene replacement and CRISPR/Cas9 gene editing (PubMed: 32810115). These strategies aim to restore or correct CRX function to halt or reverse retinal degeneration in patients with loss-of-function or dominant-negative mutations.
Gene augmentation to provide functional copies of the CRX gene or gene editing to correct dominant-negative mutations (PubMed: 32810115).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cone-rod homeobox protein (CRX) (CRX).